Dr. Lal PathLabs has announced a series of strategic decisions following its Board of Directors meeting on April 30, 2026. These include the approval of audited financial results, a final dividend, a significant acquisition, and key appointments.
The company declared a final dividend of ₹4 per equity share, representing a 40% payout on the face value of ₹10 per share, for the financial year ending March 31, 2026. This dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM), with the record date set for June 26, 2026. The dividend will be credited within 30 days following member approval.
In a strategic move, Dr. Lal PathLabs will acquire a 100% stake in Shahbazkers Diagnostic Centre Private Limited, making it a wholly-owned subsidiary. This acquisition is part of the company’s expansion strategy, aimed at strengthening its market presence.
Additionally, the company announced the incorporation of a wholly-owned subsidiary in Dubai, United Arab Emirates, named Dr. Lal PathLabs FZCO, pending necessary regulatory approvals.
The Board also confirmed the re-appointment of (Hony) Brig. Dr. Arvind Lal, Padma Shri, as Executive Chairman and Whole-Time Director, and Mr. Rajit Mehta as a Non-Executive Independent Director, both for five-year terms commencing in 2027 and 2026, respectively.
Furthermore, Dr. Reena Nakra and Dr. Saloni Khera have been designated as Senior Management Personnel, effective April 30, 2026, enhancing the company’s leadership team.
The company has also re-appointed M/s Ernst & Young LLP as Internal Auditors and M/s A.G. Agarwal & Associates as Cost Auditors for the financial year 2026-27.
In terms of employee benefits, Dr. Lal PathLabs has allotted 82,750 equity shares under its Employee Stock Option Plan 2022, increasing its paid-up equity share capital to ₹1,67,63,77,700.
The 32nd AGM is scheduled for July 25, 2026, via video conferencing.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).